Ciglitazone is a potent and selectivePPARγagonist (EC₅₀=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone inducesapoptosisaccompanied by activation ofp38 MAPKand nuclear translocation ofapoptosisinducing factor (AIF) in opossum kidney (OK) renal epithelial cells^[1][2][3][4].

Ciglitazone (0-20 μM; 24 hours) induces apoptosis through PPAR-independent mechanism. Ciglitazone causes generation of ROS and an increase in intracellular Ca^2+[4].

In C57BL/6J-ob/ob mice, Ciglitazone (100 mg/kg/day; 2 days) elicits a drastic fall in blood glucose. Regranulation of islet beta-cells and increased pancreatic insulin content are observed in ob/ob mice treated for 41-44 days with 100 mg/kg/day Ciglitazone^[3].

333.45

Solid

C₁₈H₂₃NO₃S

74772-77-3

环格列酮；酪里达唑

Room temperature in continental US; may vary elsewhere.

DMSO : 100 mg/mL(299.90 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。